Details

Autor(en) / Beteiligte

• Moog, F
• Bangerter, M
• Diederichs, C G
• Guhlmann, A
• Kotzerke, J
• Merkle, E
• Kolokythas, O
• Herrmann, F
• Reske, S N

Titel

Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging

Ist Teil von

• Radiology, 1997-06, Vol.203 (3), p.795

Ort / Verlag

United States

Erscheinungsjahr

1997

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• To compare 2-deoxy-2-[fluorine-18]fluoro-D-glucose (FDG) positron emission tomography (PET) with computed tomography (CT) in primary nodal staging of malignant lymphoma. Sixty consecutive patients with untreated, histopathologically proved malignant lymphoma (aged 7-72 years; 33 with non-Hodgkin lymphoma, 27 with Hodgkin disease) underwent FDG PET and contrast material-enhanced CT for nodal staging. Lymph node regions identified at both CT and PET were regarded as actual locations of disease. Discordant results were verified with biopsy or clinical follow-up whenever possible. One hundred sixty of 740 evaluated lymph node regions were identified as diseased at both CT and PET. Of the 25 additional regions seen with PET, seven were true-positive; two, false-positive; and 16, unresolved. CT showed six additional disease manifestations; three were false-positive, and three were unresolved. Staging was changed in the four patients with the seven confirmed additional PET findings: from stage I to II in one patient and from stage II to III in three patients. Staging was changed from stage II to I in one of the three patients with false-positive CT findings. FDG PET may be more accurate for detecting nodal lymphoma than incremental CT.